Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | SCN1A | P35498 | 1/20 | 0.37 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.37 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3550650 | 0.75 | ARG1 (0.31) | — | |
| SCHEMBL2303259 | 0.72 | ALDH1A1 (0.33) | ALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL13846152 | 0.72 | SMN1; SMN2 (0.40) | EPHX1ALDH1A1SMN1; SMN2LMNACYP1A2 | |
| SCHEMBL3546760 | 0.71 | KDM4E (0.36) | EPHX1ALDH1A1SMN1; SMN2RECQLKDM4E | |
| SCHEMBL21088943 | 0.70 | EPHX1 (0.41) | EPHX1ALDH1A1SMN1; SMN2LMNACYP1A2 | |
| SCHEMBL19138721 | 0.68 | SHBG (0.36) | EPHX1ALDH1A1SMN1; SMN2RECQLKDM4E | |
| SCHEMBL3546758 | 0.67 | EPHX2 (0.39) | EPHX1ALDH1A1RECQLKDM4EPOLB | |
| SCHEMBL16290076 | 0.67 | EPHX1 (0.40) | EPHX1ALDH1A1SMN1; SMN2RECQLLMNA | |
| SCHEMBL19996808 | 0.66 | KDM4E (0.42) | EPHX1ALDH1A1SMN1; SMN2LMNACYP1A2 | |
| SCHEMBL23451474 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709471-B2 | Compounds | ASTRAZENECA AB (SE) | 2010-05-04 | — | — | US | disclosed |
| US-20080009482-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009482-A1 | NOVEL COMPOUNDS | CYP11B2, CYP11B1, CYP46A1 | EPHX1 730/4885ALDH1A1 422/4885SMN1; SMN2 1059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.